141 assets in Hodgkins Lymphoma

Therapeutic assets addressing Hodgkins Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pentoxifylline Hodgkins Lymphoma	University of Guadalajara	P4	B (56)
Anti-Cd30/Cd16A Monoclonal Antibody Afm13 Hodgkins Lymphoma	Affimed GmbH	P2	CCC (55)
Azacitidine Hodgkins Lymphoma	Therapeutic Advances in Childhood Leukemia Consortium	P2	CCC (54)
Equine Atg Hodgkins Lymphoma	Instituto Nacional de Cancer, Brazil	P2	CCC (54)
cd30.car-t Hodgkins Lymphoma	Tessa Therapeutics	P2	CCC (53)
Daratumumab Hodgkins Lymphoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P1/2	CCC (53)
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (53)
Isatuximab Hodgkins Lymphoma	Divaya Bhutani	P2	CCC (53)
M-Sympathol Hodgkins Lymphoma	Affimed GmbH	P2	CCC (53)
NK-92 Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (53)
Valganciclovir Hodgkins Lymphoma	Viracta Therapeutics, Inc.	P2	CCC (53)
Yttrium Y 90 Basiliximab Hodgkins Lymphoma	City of Hope Medical Center	P2	CCC (53)
ab-205 Hodgkins Lymphoma	Angiocrine Bioscience	P3	CCC (52)
Allogeneic Human Umbilical Cord Blood Hodgkins Lymphoma	Leland Metheny	P2	CCC (52)
Atezolizumab Hodgkins Lymphoma	Fondazione Italiana Linfomi - ETS	P2	CCC (52)
Azacytidine Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (52)
Hpc, Cord Blood Hodgkins Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (52)
Polatuzumab Vedotin Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (52)
Tifcemalimab Hodgkins Lymphoma	Shanghai Junshi Bioscience Co., Ltd.	P3	CCC (52)
Toripalimab Hodgkins Lymphoma	Shanghai Junshi Bioscience Co., Ltd.	P3	CCC (52)
Letermovir Hodgkins Lymphoma	City of Hope Medical Center	P2	CCC (50)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine Hodgkins Lymphoma	City of Hope Medical Center	P2	CCC (50)
Recombinant Human Granulocyte Colony-Stimulating Factor Hodgkins Lymphoma	City of Hope Medical Center	P2	CCC (50)
Abatacept Recombinant Hodgkins Lymphoma	Leland Metheny	P2	CCC (48)
Begev Hodgkins Lymphoma	Fondazione Italiana Linfomi - ETS	P1/2	CCC (48)
Blinatumomab Hodgkins Lymphoma	St. Jude Children's Research Hospital	P2	CCC (48)
cd45ra-depleted dli Hodgkins Lymphoma	St. Jude Children's Research Hospital	P2	CCC (48)
cd70.car nk cells Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (48)
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer Hodgkins Lymphoma	University of Utah	P2	CCC (48)
Lentivirus Vector Ccr5 Shrna Hodgkins Lymphoma	AIDS Malignancy Consortium	P1/2	CCC (48)
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells Hodgkins Lymphoma	AIDS Malignancy Consortium	P1/2	CCC (48)
L-Methionine Hodgkins Lymphoma	St. Jude Children's Research Hospital	P2	CCC (48)
Mad Cpr 1 And 2 Hodgkins Lymphoma	New York Medical College	P2	CCC (48)
Mgta-456 Hodgkins Lymphoma	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Mosunetuzumab Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (48)
Prolgolimab Hodgkins Lymphoma	St. Petersburg State Pavlov Medical University	P2	CCC (48)
Retlirafusp Alfa Hodgkins Lymphoma	Chinese PLA General Hospital	P1/2	CCC (48)
shr2554 Hodgkins Lymphoma	Chinese PLA General Hospital	P1/2	CCC (48)
Tafasitamab Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CCC (48)
Treosulfan Hodgkins Lymphoma	Fred Hutchinson Cancer Center	P2	CCC (48)
vi-0609 Hodgkins Lymphoma	VIVUS LLC	P2	CCC (48)
Atrovastain Hodgkins Lymphoma	Assiut University	P1/2	CC (47)
Cart30 Hodgkins Lymphoma	Chinese PLA General Hospital	P1/2	CC (47)
Relatlimab Hodgkins Lymphoma	Bristol-Myers Squibb	P1/2	CC (47)
Rimiducid Hodgkins Lymphoma	M.D. Anderson Cancer Center	P2	CC (46)
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells Hodgkins Lymphoma	Medical College of Wisconsin	P1	CC (43)
Autologous Car.Cd30 Ebv Specific-Ctls Hodgkins Lymphoma	Baylor College of Medicine	P1	CC (43)
Autologous Cd30.Car-T Hodgkins Lymphoma	Tessa Therapeutics	P1	CC (43)
Cedazuridine Hodgkins Lymphoma	National Cancer Institute (NCI)	P1	CC (43)
Ebv-Specific T Cells: B Hodgkins Lymphoma	Baylor College of Medicine	P1	CC (43)

Showing 51 to 100 of 141 assets

PreviousPage 2 of 3Next